Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia.

BACKGROUND: Chloroquine was used as first-line treatment for Plasmodium falciparum or Plasmodium vivax in Indonesia before the initial launch of artemisinin combination therapy in 2004. A study to evaluate efficacies of chloroquine against P. falciparum and P. vivax was undertaken at Lampung in sou...

全面介紹

書目詳細資料
Main Authors: Sutanto, I, Endawati, D, Ling, L, Laihad, F, Setiabudy, R, Baird, J
格式: Journal article
語言:English
出版: BioMed Central 2010
_version_ 1826277740548980736
author Sutanto, I
Endawati, D
Ling, L
Laihad, F
Setiabudy, R
Baird, J
author_facet Sutanto, I
Endawati, D
Ling, L
Laihad, F
Setiabudy, R
Baird, J
author_sort Sutanto, I
collection OXFORD
description BACKGROUND: Chloroquine was used as first-line treatment for Plasmodium falciparum or Plasmodium vivax in Indonesia before the initial launch of artemisinin combination therapy in 2004. A study to evaluate efficacies of chloroquine against P. falciparum and P. vivax was undertaken at Lampung in southern Sumatra, western Indonesia in 2002. METHODS: Patients infected by P. falciparum or P. vivax were treated with 25 mg/kg chloroquine base in three daily doses over 48 hr. Finger prick blood was collected on Days 0, 2, 3, 7, 14, 21 and 28 after starting drug administration. Whole blood chloroquine and its desethyl metabolite were measured on Days-0, -3 and -28, or on the day of recurrent parasitaemia. RESULTS: 42 patients infected by P. falciparum were enrolled, and 38 fullfilled criteria for per protocol analysis. Only six of 38 (16%) showed a response consistent with senstivity to chloroquine. 25 of 32 failures were confirmed resistant by demonstrating chloroquine levels on day of recurrence exceeding the minimally effective concentration (200 ng/mL whole blood). The 28-day cumulative incidence of resistance in P. falciparum was 68% (95% CI: 0.5260 - 0.8306). Thirty one patients infected by P. vivax were enrolled, and 23 were evaluable for per protocol analysis. 15 out of 23 (65%) subjects had persistent or recurrent parasitaemia. Measurement of chloroquine levels confirmed all treatment failures prior to Day-15 as resistant. Beyond Day-15, 4 of 7 recurrences also had drug levels above 100 ng/mL and were classified as resistant. The 28-day cumulative incidence of chloroquine resistance in P. vivax was 43% (95% CI: 0.2715 - 0.6384). CONCLUSION: These findings confirm persistantly high levels of resistance to chloroquine by P. falciparum in southern Sumatra, and suggest that high-grade and frequent resistance to chloroquine by P. vivax may be spreading westward in the Indonesia archipelago.
first_indexed 2024-03-06T23:33:27Z
format Journal article
id oxford-uuid:6cd5a525-ae2b-4704-8e57-b6b51a9b498d
institution University of Oxford
language English
last_indexed 2024-03-06T23:33:27Z
publishDate 2010
publisher BioMed Central
record_format dspace
spelling oxford-uuid:6cd5a525-ae2b-4704-8e57-b6b51a9b498d2022-03-26T19:13:47ZEvaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6cd5a525-ae2b-4704-8e57-b6b51a9b498dEnglishSymplectic Elements at OxfordBioMed Central2010Sutanto, IEndawati, DLing, LLaihad, FSetiabudy, RBaird, J BACKGROUND: Chloroquine was used as first-line treatment for Plasmodium falciparum or Plasmodium vivax in Indonesia before the initial launch of artemisinin combination therapy in 2004. A study to evaluate efficacies of chloroquine against P. falciparum and P. vivax was undertaken at Lampung in southern Sumatra, western Indonesia in 2002. METHODS: Patients infected by P. falciparum or P. vivax were treated with 25 mg/kg chloroquine base in three daily doses over 48 hr. Finger prick blood was collected on Days 0, 2, 3, 7, 14, 21 and 28 after starting drug administration. Whole blood chloroquine and its desethyl metabolite were measured on Days-0, -3 and -28, or on the day of recurrent parasitaemia. RESULTS: 42 patients infected by P. falciparum were enrolled, and 38 fullfilled criteria for per protocol analysis. Only six of 38 (16%) showed a response consistent with senstivity to chloroquine. 25 of 32 failures were confirmed resistant by demonstrating chloroquine levels on day of recurrence exceeding the minimally effective concentration (200 ng/mL whole blood). The 28-day cumulative incidence of resistance in P. falciparum was 68% (95% CI: 0.5260 - 0.8306). Thirty one patients infected by P. vivax were enrolled, and 23 were evaluable for per protocol analysis. 15 out of 23 (65%) subjects had persistent or recurrent parasitaemia. Measurement of chloroquine levels confirmed all treatment failures prior to Day-15 as resistant. Beyond Day-15, 4 of 7 recurrences also had drug levels above 100 ng/mL and were classified as resistant. The 28-day cumulative incidence of chloroquine resistance in P. vivax was 43% (95% CI: 0.2715 - 0.6384). CONCLUSION: These findings confirm persistantly high levels of resistance to chloroquine by P. falciparum in southern Sumatra, and suggest that high-grade and frequent resistance to chloroquine by P. vivax may be spreading westward in the Indonesia archipelago.
spellingShingle Sutanto, I
Endawati, D
Ling, L
Laihad, F
Setiabudy, R
Baird, J
Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia.
title Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia.
title_full Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia.
title_fullStr Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia.
title_full_unstemmed Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia.
title_short Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia.
title_sort evaluation of chloroquine therapy for vivax and falciparum malaria in southern sumatra western indonesia
work_keys_str_mv AT sutantoi evaluationofchloroquinetherapyforvivaxandfalciparummalariainsouthernsumatrawesternindonesia
AT endawatid evaluationofchloroquinetherapyforvivaxandfalciparummalariainsouthernsumatrawesternindonesia
AT lingl evaluationofchloroquinetherapyforvivaxandfalciparummalariainsouthernsumatrawesternindonesia
AT laihadf evaluationofchloroquinetherapyforvivaxandfalciparummalariainsouthernsumatrawesternindonesia
AT setiabudyr evaluationofchloroquinetherapyforvivaxandfalciparummalariainsouthernsumatrawesternindonesia
AT bairdj evaluationofchloroquinetherapyforvivaxandfalciparummalariainsouthernsumatrawesternindonesia